Extracorporeal perfusion for the treatment of acute liver failure

Annals of Surgery

Volumn 231, Issue 4, 2000, Pages 460-470

  Stockmann, Henricus B A C ^a   Hiemstra, Coen A ^a   Marquet, Richard L ^a   IJzermans, Johannes N M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ARTIFICIAL LIVER; EXTRACORPOREAL CIRCULATION; LIVER FAILURE; LIVER FUNCTION; LIVER PERFUSION; MORTALITY; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; TREATMENT OUTCOME;

ANIMALS; HEMOPERFUSION; HUMANS; LIVER FAILURE, ACUTE; LIVER, ARTIFICIAL; PERFUSION; SWINE; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME;

EID: 0034111037     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-200004000-00003     Document Type: Article

References (90)

1. Lee W. Acute liver failure. N Engl J Med 1994; 329:1862-1872.
2. Chang TMS. Haemoperfusions over a microencapsulated adsorbent in a patient with hepatic with hepatic coma. Lancet 1972; 2:1371-1372.
3. Kiley JE, Welch HF, Pender JC, Welch CS. Removal of blood ammonia by hemodialysis. Proc Soc Exp Biol Med 1956; 91:489-490.
4. Silk DB, Trewby PN, Chase RA, et al. Treatment of fulminant hepatic failure by polyacrylonitrile-membrane haemodialysis. Lancet 1977; 2:1-3.
5. Denis J, Opolon P, Nusinovici V, Granger A, Darnis F. Treatment of encephalopathy during fulminant hepatic failure by haemodialysis with high-permeability membrane. Gut 1978; 19:787-793.
6. Denis J, Opolon P, Delorme ML, Granger A, Darnis F. Long-term extracorporeal assistance by continuous haemofiltration during fulminant hepatic failure. Gastroenterol Clin Biol 1979; 3:337-348.
7. Rakela J, Kurtz SB, McCarthy JT, et al. Postdilution hemofiltration in the management of acute hepatic failure: a pilot study. Mayo Clin Proc 1988; 63:113-118.
8. Lee C, Tink A. Exchange transfusion in hepatic coma: report of a case. Med J Aust 1958; 1:40-42.
9. Trey C, Burns DG, Saunders SJ. Treatment of hepatic coma by exchange blood transfusion. N Engl J Med 1966; 274:473-481.
10. Ritt DJ, Whelan G, Werner DJ, Eigenbrodt EH, Schenker S, Combes B. Acute hepatic necrosis with stupor or coma. An analysis of 31 patients. Medicine 1969; 48:151-172.
11. Mckechnie JC, Hersh T. Exchange transfusion in hepatic coma. A review of 19 cases. Am J Gastroenterol 1971; 56:17-43.
12. Redeker AG, Yamahiro HS. Controlled trial of exchange-transfusion therapy in fulminant hepatitis. Lancet 1973; 1:3-6.
13. Lepore MJ, Stutman LJ, Bonanno CA, Conklin EF, Robilotti JG Jr, McKenna PJ. Plasmapheresis with plasma exchange in hepatic coma. II Fulminant viral hepatitis as a systemic disease. Arch Intern Med 1972; 129:900-907.
14. Haapanen E, Tiula E. Plasmapheresis with albumin as main substitute in acute hepatic coma. Scand J Gastroenterol 1972; 7:75-83.
15. Matsabura S, Okabe K, Ouchi K, et al. Continuous removal of middle molecules by hemofiltration in patients with acute liver failure. Crit Care Med 1990; 18:1331-1338.
16. Yamazaki Z, Kanai F, Idezuki Y, Inoue N. Extracorporeal methods of liver failure treatment. Biomater Artif Cells Artif Organs 1987; 15: 667-675.
17. Ching NP, Nealon TF Jr, Gibbon JH Jr. An extracorporeal device for hepatic coma. JAMA 1963; 183:350-354.
18. Juggi JS. Extracorporeal cation-exchange circuits in the treatment of hyperammonaemia of hepatic failure. Med J Aust 1973; 60:926-930.
19. Gimson AES, Mellon PJ, Braude S, Canalese J, Williams R. Earlier charcoal haemoperfusion in fulminant hepatic failure. Lancet 1980; 1:173-175.
20. Gazzard BG, Weston MJ, Murray-Lyon IM, et al. Charcoal haemoperfusion in the treatment of fulminant hepatic failure. Lancet 1974; 1:1301-1307.
21. Hughes R, Williams R. Clinical experience with charcoal and resin hemoperfusion. Semin Liver Dis 1986; 6:164-173.
22. Gimson AES, Mellon PJ, Braude S, Canalese, Williams R. Earlier charcoal haemoperfusion in fulminant hepatic failure. Lancet 1982; 2:681-683.
23. O'Grady JG, Gimson AES, O'Brien CJ, Pucknell A, Hughes RD, Williams R. Controlled trials of charcoal haemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1998; 94:1186-1192.
24. Sutherland DER, Numata M, Matas AJ, Simmons RL, Najarian JS. Hepatocellular transplantation in acute liver failure. Surgery 1977; 82:124-132.
25. Reid LM, Jefferson DM. Culturing hepatocytes and other ifferentiated cells. Hepatology 1984; 4:548-559.
26. Stockmann HBAC, Tompkins RG, Berthiaume F. Expression of long-term liver-specific function by adult rat hepatocytes cultured on microcarriers. Tissue Eng 1997; 3:267-279.
27. Matsamura KN, Guevera GR, Huston H, et al. Hybrid bioartificial liver in hepatic failure: preliminary clinical report. Surgery 1987; 101:99-103.
28. Margulis MS, Erukhimov EA, Andreiman LA, Viksna LM. Temporary organ substitution by hemoperfusion through suspension of active donor hepatocytes in a total complex of intensive therapy in patients with acute hepatic insufficiency. Resuscitation 1989; 18:85-94.
29. Shnyra A, Bocharov A, Bochkova N, Spirov V. Bioartificial liver using hepatocytes on Biosilon microcarriers: treatment of chemically induced acute hepatic failure in rats. Artif Organs 1991; 15:189-197.
30. Yanagi K, Ookawa K, Mizuno S. Performance of a new hybrid bioartificial liver support system using hepatocytes entrapped within a hydrogel. ASAIO Trans 1989; 35:570-572.
31. Uchino J, Tsuburaya T, Kumagai F, et al. A hybrid bioartificial liver composed of multiplated hepatocyte monolayers. ASAIO Trans 1988; 34:972-977.
32. Uchino J, Matsue H, Takahashi M, et al. A hybrid artificial liver system. Function of cultured monolayer pig hepatocytes in plasma from hepatic failure patients. ASAIO Trans 1991; 37:M337-M338.
33. Koike M, Matsushita M, Taguchi K, Uchino J. Function of culturing monolayer hepatocytes by collagen gel coating and coculture with nonparenchymal cells. Artif Organs 1996; 20:186-192.
34. Taguchi K, Matsushita M, Takahashi M, Uchino J. Development of a bioartificial liver with sandwiched-cultured hepatocytes between two collagen gel layers. Artif Organs 1996; 20:178-185.
35. Nyberg SL, Platt JL, Shirabe K, Payne WD, Hu W-S, Cerra F. Immunoprotection of xenocytes in a hollow fiber bioartificial liver. ASAIO J 1992; 38:M463-467.
36. Tompkins RG, Carter EA. Enzymatic function of alginate immobilized rat hepatocytes. Biotechnol Bioeng 1988; 31:11-18.
37. Dunn JC, Yarmush ML, Koebe HG, Tompkins RG. Hepatocyte function and extracellular matrix geometry: long-term culture in a sandwich configuration. FASEB J 1989; 3:174-177.
38. Enat R, Jefferson DM, Ruiz-Opazo N, Gatmaitan Z, Leinwand LA, Reid LM. Hepatocyte proliferation in vitro: its dependence on the use of serum-free hormonally defined medium and substrata of extracellular matrix. Proc Natl Acad Sci USA 1984; 81:1411-1415.
39. Jauregi HO, McMillan PN, Driscoll J, Naik S. Attachment and long-term survival of adult rat hepatocytes in primary monolayer cultures: comparison of different substrata and tissue culture media formulations. In Vitro Cell Dev Biol 1986; 22:13-22.
40. Nyberg SL, Shatford RA, Peshwa MV, White JG, Ceraa FB, Hu W-S. Evaluation of a hepatocyte-entrapment hollow fiber bioreactor: a potential bioartificial liver. Biotechnol Bioeng 1993; 41:194-203.
41. Sielaff TD, Hu MY, Amiot B, et al. Gel-entrapment bioartificial liver therapy in galactosamine hepatitis. J Surg Res 1995; 59:179-184.
42. Nyberg SL, Mann HJ, Remmel RP, Hu W-S, Cerra FB. Pharmacokinetic analysis verifies P450 function during in vitro and in vivo application of a bioartificial liver. ASAIO J 1993; 39:M252-M256.
43. Sielaff TD, Nyberg SL, Rollins MD, et al. Characterization of the three-compartment gel-entrapment porcine hepatocyte bioartificial liver. Cell Biol Toxicol 1997; 13:357-364.
44. Sussman NL, Chong MG, Koussayer T, et al. Reversal of fulminant hepatic failure using an extracorporeal liver assist device. Hepatology 1992; 16:60-65.
45. Sussman NL, Gislason GT, Conlin CA, Kelly JH. The Hepatix extracorporeal liver assist device: initial clinical experience. Artif Organs 1994; 18:390-396.
46. Ellis AJ, Hughes RD, Wendon JA, et al. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 1996; 24:1446-1451.
47. Nyberg SL, Remmel RP, Mann HJ, Peshwa MV, Hu W, Cerra FB. Primary hepatocytes outperform Hep-G2 cells as the source of biotransformation functions in a bioartificial liver. Ann Surg 1994; 1:59-67.
48. Demetriou AA, Whiting J, Levenson SM, et al. New method of hepatocyte transplantation and extracorporeal liver support. Ann Surg 1986; 204:259-271.
49. Giorgio TD, Moscioni AD, Rozga J, Demetriou AA. Mass transfer in a hollow fiber device used as a bioartificial liver. ASAIO Trans 1993; 38:886-892.
50. Rozga J, Williams F, Ro M, et al. Development of a bioartificial liver: properties and function of a hollow fiber module inoculated with liver cells. Hepatology 1993; 17:258-265.
51. Rozga J, Holzman MD, Ro M, et al. Development of a hybrid bioartificial liver. Ann Surg 1993; 217:502-511.
52. Watanabe FD, Mullon CJ, Hewitt WR, et al. Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. Ann Surg 1997; 225:484-494.
53. Thomson JA, Itskovitz-Elder J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282:1145-1147.
54. Bernard C. Sur le mechanisme de la formation du sucre dans la foie. CR Acad Sci (Par) 1855; 41:461.
55. Otto JJ, Pender JC, Cleary JH, Sensenig DM, Welch CS. The use of a donor liver in experimental animals with elevated blood ammonia. Surgery 1958; 43:301-309.
56. Eiseman B, Liem DS, Rafucci F. Heterologous liver perfusion in treatment of hepatic failure. Ann Surg 1965; 162:329-345.
57. Watts JM, Douglas MC, Dudley HAF, Gurr FW, Owen JA. Heterologous liver perfusion in acute hepatic failure. Br Med J 1967; 2:341-345.
58. Abouna GM, Kirkley JR, Hull CJ, Ashcroft T, Kerr DNS. Treatment of hepatic coma by extracorporeal pig-liver perfusion. Lancet 1969; 1:64-68.
59. Ranek L, Hansen RI, Hilden M, et al. Pig liver perfusion in the treatment of acute hepatic failure. Scand J Gastroenterol 1971(suppl 9):161-169.
60. Pharboo SP, Kennedy J, James IM, et al. Extracorporeal pig-liver perfusion in treatment of hepatic coma due to fulminant hepatitis. Lancet 1971; 1:659-665.
61. Tung LC, Haring R, Weber D, Waldschmidt J. Experience in the treatment of hepatic coma by extracorporeal liver perfusion. In: Brunner G, Schmidt FW, eds. Artificial Liver Support. Berlin: Springer-Verlag, 1981:274-279.
62. Chari RS, Collins BH, Magee JC, et al. Brief report: treatment of hepatic failure with ex vivo pig-liver perfusion followed by liver transplantation. N Engl J Med 1994; 331:234-237.
63. Levy MF, Crippin J, Stutton S, et al. Successful transgenic porcine liver perfusion as a bridge to human liver transplantation. Presented at the Transplantation Society XVII World Congress in Montreal, 1998.
64. Filiponi F, Abouna GM, Boggi U, et al. Ex vivo liver perfusion: a successful technique of liver support. Gastroenterology 1998; 114: A1240.
65. Stevens RB, Platt JL. The pathogenesis of hyperacute xenograft rejection. Am J Kidney Dis 1992; 20:414-421.
66. Vaughan HA, Loveland BE, Sandrin MS. GAL-alpha (1,3) GAL is the major xenoepitope expressed on pig endothelial cells recognised by naturally occurring cytotoxic human antibodies. Transplantation 1994; 58:879-828.
67. Soares M, Havaux X, Van Beneden R, et al. Characterisation of rat anti-guinea pig circulating xenoreactive natural antibodies and secreting cells. Transplant Proc 1995; 27:282-285.
68. Galili U, Mandrell RE, Hamahdeh RM, Shohet SB, Griffis JM. Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora. Infect Immun 1988; 56:1730.
69. Schaapherder AF, Gooszen HG, te Bulte MT, Daha MR. Human complement activation via the alternative pathway on porcine endothelium initiated by IgA antibodies. Transplantation 1995; 60:287-291.
70. Parker W, Bruno D, Holzknecht ZE, Platt JL. Characterization and affinity isolation of xenoreactive human natural antibodies. J Immunol 1994; 153:3791-3803.
71. Schraa EO, Stockmann HBAC, Scheringa M, Broekhuizen AJ, Marquet RL, Ijzermans JNM. IgG, but not IgM, mediates hyperacute rejection in hepatic xenografting. Xenotransplantation 1998; 6:110-116.
72. Ellison RT, Horsburgh RC, Curd J. Complement levels in patients with hepatic dysfunction. Dig Dis Sci 1990; 35:231-235.
73. Grinyo JM, Cruzado JM, Riera M, et al. Functional and pathologic outcome after complement inactivation in a pig kidney-human blood xenoperfusion model. Transplant Proc 1997; 29:2318-2321.
74. Schön MR, Lemmens HP, Neuhaus P, et al. Improved xenogeneic extracorporeal liver perfusion. Transplant Proc 1994; 26:1293-1297.
75. Tuso PJ, Cramer DV, Yasunaga C, Cosenza CA, Wu GD, Makowka L. Removal of natural human xenoantibodies to pig vascular endothelium by perfusion of blood through pig kidneys and livers. Transplantation 1993; 55:1375-1378.
76. Tector AJ, Elias N, Rosenberg L, et al. Mechanisms of resistance to injury in pig livers perfused with blood from patients in liver failure. Transplant Proc 1997; 29:966-969.
77. Collins BH, Chari RS, Magee JC, et al. Mechanisms of injury in porcine livers perfused with blood of patients with fulminant hepatic failure. Transplantation 1994; 58:1162-1171.
78. Cotterell AH, Collins BH, Parker W, Harland RC, Platt JL. The humoral immune response in humans following cross-perfusion of porcine organs. Transplantation 1995; 60:861-868.
79. McKenzie IFC, Osman N, Cohney S, Sandrin MS. Strategies to overcome hyperacute rejection of pig-to-human xenografts. Transplant Proc 1997; 29:973-974.
80. Pöhlein C, Pascher A, Baumann P, et al. Transgenic porcine livers reduce liberation of humoral mediators during xenoperfusion with human blood. Transplant Proc 1996; 28:772-774.
81. Yagi T, Satoh S, Kanazawa A, et al. Extracorporeal xenoperfusion of the pig liver as a liver assist device: effects of prostaglandin E1 and soluble complement receptor type 1. Transplant Proc 1998; 30:74-75.
82. Pascher A, Pöhlein C, Stangl M, et al. Application of immunoapheresis for delaying hyperacute rejection during isolated xenogeneic pig liver perfusion. Transplantation 1997; 63:867-875.
83. Abouna GM, Serrou B, Boehmig HG, Amemiya H, Martmeau G. Long-term hepatic support by intermittent multi-species liver perfusions. Lancet 1970; 1:391-396.
84. Te Velde AA, Flendrig LM, Ladiges NC, Chamuleau RA. Immunological consequences of the use of xenogeneic hepatocytes in a bioartificial liver for acute liver failure. Int J Artif Organs 1997; 20:229-233.
85. Gerlach J, Jorres A, Trost O, et al. Side effects of hybrid liver support therapy: TNF-alpha liberation in pigs, associated with extracorporeal bioreactors. Int J Artif Organs 1993; 16:604-608.
86. Baquerizo A, Mhoyan A, Shirwan H, et al. Xenoantibody response of patients with severe acute liver failure exposed to porcine antigens following treatment with a bioartificial liver. Transplant Proc 1997; 29:964-965.
87. Triulzi DJ, Jochum EA, Marino IR, Strazl TE. Heteroagglutinins and their significance in baboon hepatic xenotransplantation. Transplantation 1995; 60:127-131.
88. Patience C, Takeuchi Y, Weiss RA. Infection of human cells by an endogenous retrovirus of pigs. Nat Med 1997; 3:282-286.
89. Martin U, Steinhoff G, Kiessig V, et al. Porcine endogenous retrovirus (PERV) was not transmitted from transplanted porcine endothehal cells to baboons in vivo. Transplant Int 1998; 11:247-251.
90. Heneine W, Tibell A, Switzer B, et al. Absence of evidence of infection with the porcine endogenous retrovirus (PERV) in human recipients of pig islet cells. Transplantation Society XVII World Congress, Montreal, 1998.